Free Trial

biote (BTMD) Competitors

biote logo
$2.89 -0.05 (-1.70%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$2.89 0.00 (0.00%)
As of 10/24/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BTMD vs. ARCT, KALV, ESPR, INBX, PRTA, CTMX, CRVS, LXEO, ORGO, and CYRX

Should you be buying biote stock or one of its competitors? The main competitors of biote include Arcturus Therapeutics (ARCT), KalVista Pharmaceuticals (KALV), Esperion Therapeutics (ESPR), Inhibrx Biosciences (INBX), Prothena (PRTA), CytomX Therapeutics (CTMX), Corvus Pharmaceuticals (CRVS), Lexeo Therapeutics (LXEO), Organogenesis (ORGO), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry.

biote vs. Its Competitors

biote (NASDAQ:BTMD) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

21.7% of biote shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 24.0% of biote shares are held by company insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Arcturus Therapeutics had 38 more articles in the media than biote. MarketBeat recorded 45 mentions for Arcturus Therapeutics and 7 mentions for biote. biote's average media sentiment score of 0.79 beat Arcturus Therapeutics' score of 0.06 indicating that biote is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
biote
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcturus Therapeutics
3 Very Positive mention(s)
8 Positive mention(s)
12 Neutral mention(s)
7 Negative mention(s)
0 Very Negative mention(s)
Neutral

biote presently has a consensus target price of $6.00, suggesting a potential upside of 107.61%. Arcturus Therapeutics has a consensus target price of $31.71, suggesting a potential upside of 182.66%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than biote.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
biote
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Arcturus Therapeutics
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64

biote has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
biote$197.19M0.72$3.16M$0.903.21
Arcturus Therapeutics$152.31M2.00-$80.94M-$2.23-5.03

biote has a net margin of 15.73% compared to Arcturus Therapeutics' net margin of -49.26%. biote's return on equity of -21.00% beat Arcturus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
biote15.73% -21.00% 18.26%
Arcturus Therapeutics -49.26%-24.87%-17.75%

biote has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500.

Summary

biote beats Arcturus Therapeutics on 9 of the 17 factors compared between the two stocks.

Get biote News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BTMD vs. The Competition

MetricbioteMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$142.88M$11.08B$6.21B$10.81B
Dividend YieldN/A1.88%5.72%4.80%
P/E Ratio3.2121.4531.6030.98
Price / Sales0.7231.07595.06133.64
Price / Cash3.7725.0837.2561.86
Price / Book-1.043.5012.056.61
Net Income$3.16M$210.63M$3.34B$277.10M
7 Day Performance1.76%0.74%1.94%2.57%
1 Month Performance-3.34%2.73%6.88%3.20%
1 Year Performance-43.66%-7.76%56.06%33.22%

biote Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTMD
biote
2.6564 of 5 stars
$2.89
-1.7%
$6.00
+107.6%
-43.7%$142.88M$197.19M3.21194News Coverage
Analyst Upgrade
ARCT
Arcturus Therapeutics
3.4416 of 5 stars
$21.51
+4.1%
$50.57
+135.1%
-40.8%$561.01M$152.31M-9.65180Trending News
Analyst Downgrade
Analyst Revision
KALV
KalVista Pharmaceuticals
3.6166 of 5 stars
$11.54
+4.0%
$26.43
+129.0%
-4.7%$560.81MN/A-2.93100Analyst Forecast
ESPR
Esperion Therapeutics
3.7164 of 5 stars
$2.82
+2.5%
$7.00
+148.2%
+29.0%$554.46M$332.31M-5.76200Analyst Forecast
INBX
Inhibrx Biosciences
2.0358 of 5 stars
$38.22
+2.6%
N/A+272.7%$539.58M$200K-3.61166Trending News
Analyst Forecast
Gap Up
PRTA
Prothena
2.5264 of 5 stars
$10.37
+4.5%
$20.50
+97.7%
-35.8%$533.99M$135.16M-1.84130Positive News
CTMX
CytomX Therapeutics
4.3621 of 5 stars
$3.74
+16.9%
$5.42
+44.8%
+216.5%$527.72M$138.10M6.68170Analyst Forecast
CRVS
Corvus Pharmaceuticals
2.0982 of 5 stars
$7.47
+6.1%
$13.75
+84.1%
-11.6%$524.58MN/A-7.4030Positive News
Analyst Forecast
LXEO
Lexeo Therapeutics
2.8242 of 5 stars
$9.22
-3.8%
$18.86
+104.5%
-2.8%$517.33M$650K-2.8358Trending News
Analyst Forecast
Analyst Revision
ORGO
Organogenesis
4.0034 of 5 stars
$4.08
+1.0%
$7.33
+79.7%
+52.1%$512.51M$482.04M-29.14950Analyst Forecast
CYRX
CryoPort
2.895 of 5 stars
$10.54
+4.2%
$12.56
+19.1%
+56.2%$506.68M$228.38M7.921,186Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:BTMD) was last updated on 10/26/2025 by MarketBeat.com Staff
From Our Partners